Loading...
•
Jun 30, 2024
Intensity Therapeutics Q2 2024 Earnings Report
Intensity Therapeutics' financial performance and corporate activities were reported for Q2 2024.
Key Takeaways
Intensity Therapeutics reported a net loss of $5.0 million for the second quarter of 2024, compared to a net loss of $3.7 million for the same period in 2023. As of June 30, 2024, cash, cash equivalents and marketable debt securities totaled $6.3 million, which is expected to fund operations into the first quarter of 2025. The company dosed its first patient in a Phase 3 study in metastatic soft tissue sarcoma and entered into a collaboration agreement with SAKK for a Phase 2 study in early-stage breast cancer.
First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma.
Collaboration agreement established with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized study in early-stage breast cancer in Europe.
Cash and investments of $6.3 million are expected to fund operations into the first quarter of 2025.
Net loss was $5.0 million for the three months ended June 30, 2024, compared to a net loss of $3.7 million for the three months ended June 30, 2023.
Forward Guidance
The Company expects that its cash, cash equivalents and marketable debt securities of $6.3 million as of June 30, 2024, will be sufficient to fund operations into the first quarter in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...